Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat PharmaBOM:542934 67 PB Ratio is 1.20 as of Aug. 16, 2026, which is 37% below its 10-year median of 1.90. GuruFocus rates BOM:542934 with a GF Score™ of 67/100 and a GF Value™ of ₹70.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 112 Medical Distribution companies, Chandra Bhagat Pharma ranks worse than 56.25% on this metric.
The historical rank and industry rank for Chandra Bhagat Pharma's PB Ratio or its related term are showing as below:
BOM:542934'
s PB Ratio Range Over the Past 10 Years
Min: 0.72 Med: 1.9 Max: 4.08
Current: 1.2
During the past 10 years, Chandra Bhagat Pharma's highest PB Ratio was 4.08. The lowest was 0.72. And the median was 1.90.
BOM:542934's PB Ratio is ranked worse than 56.25% of 112
companies
in the Medical Distribution industry
Industry Median: 1.025
vs BOM:542934: 1.20
During the past 12 months, Chandra Bhagat Pharma's average Book Value Per Share Growth Rate was 10.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Chandra Bhagat Pharma was 51.30% per year. The lowest was 2.30% per year. And the median was 6.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Chandra Bhagat Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chandra Bhagat Pharma (BOM:542934) has a PB Ratio of 1.20 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chandra Bhagat Pharma and its competitors. This is 37% below median its historical median of 1.90. Over the past decade, Chandra Bhagat Pharma's PB Ratio has ranged from 0.72 to 4.08. According to the industry distribution chart, Chandra Bhagat Pharma ranks #63 out of 112 companies in the Medical Distribution industry, placing it in the top 56.2%.
Is Chandra Bhagat Pharma's PB Ratio too high?
Chandra Bhagat Pharma's current PB Ratio of 1.20 is 37% below median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 4.08. The Medical Distribution industry median PB Ratio is 1.03. Chandra Bhagat Pharma's value of 1.20 is 17.1% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #63 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #63 out of 112 companies for PB Ratio. This places Chandra Bhagat Pharma in the lower half of its industry. The industry median PB Ratio is 1.03. Chandra Bhagat Pharma's value of 1.20 is 17.1% above this benchmark. Historically, Chandra Bhagat Pharma's own PB Ratio has ranged from 0.72 to 4.08 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 1.03, Chandra Bhagat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current PB Ratio of 1.20 is 17.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current PB Ratio is 1.20, which is 37% below median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹70.14, compared to a current price of ₹52.50 — trading 25.1% below its estimated fair value. The current PB Ratio is 1.20, which is 37% below median its 10-year median of 1.90 and 17.1% above the Medical Distribution industry median of 1.03. Chandra Bhagat Pharma's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current PB Ratio is 1.20 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹52.50 is trading 25.1% below its estimated GF Value™ of ₹70.14.
GuruFocus considers Chandra Bhagat Pharma to be Modestly Undervalued.
Key valuation signals for BOM:542934:
PB Ratio: 1.20 (37% below median its 10-year median of 1.90)
GF Value™: ₹70.14 vs. price of ₹52.50 (25.1% below fair value)
Industry Position: 17.1% above the Medical Distribution median (#63 of 112)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
67GF Score
Get the complete analysis for BOM:542934
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
